Candel Therapeutics

Candel Therapeutics, Inc. (CADL), a U.S.-based biopharmaceutical company, has announced the acquisition of two U.S. firms, Vignette Bio and TRC 2004 Inc. The move allows Candel to secure Vignette Bio’s BCMA/CD bispecific antibody (BsAb) and TRC 2004’s CD3/CD20 BsAb. Vignette Bio, a joint venture between Shanghai-based EpimAb Biotherapeutics, Inc. and…